Rosalind Study

How Patient Diversity in Clinical Trials Improves Cancer Research

Patient Population diversity is essential to discovering the biology of exceptional cancer survival

Happy 14 Juillet! French oncology centers are an important part of our oncology network

Liberté, Égalité, Fraternité… and a shared commitment to advance cancer research

Why do exceptional survivors hold the blueprint to defeating cancer?

We're turning the biology of exceptional cancer survivors into the next generation of cancer medicines

What if improving cancer care started with listening more carefully to patients?

Patient perspective is the driving force behind our Rosalind Study

New strategic partnerships: our global oncology network continues to expand!

Together, we're building the world's most comprehensive database of exceptional cancer survivors

What happens when an exceptional cancer survivor is identified?

CHUV Lausanne received their Rosalind trophy!

Our partnership with CHUV plays a critical role in advancing our Rosalind Study

Sharing Insights: our CEO Nicolas Wolikow Speaks at PSCC Annual Event!

Biotech startups and pharmaceutical companies can strengthen partnerships to accelerate drug development

The Rosalind Study | Decoding Exceptional Cancer Survival Across GBM, ES-SCLC and mPDAC

The Rosalind Study | Three cohorts, one mission: decoding exceptional Cancer survival across GBM, ES-SCLC and mPDAC

A Strategic Partnership to Rethink Pancreatic Cancer Treatment: Cure51 × CRCM × Institut Paoli-Calmettes

Cure51's CEO Nicolas Wolikow: How does AI help advance our Rosalind Study?

Celebrating a huge Rosalind Study milestone: 115+ worldwide partner oncology centers!

Rosalind Study Milestone: 115+ Centers Join Cure51’s International Oncology Network